A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Public ClinicalTrials.gov record NCT06891066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily
Study identification
- NCT ID
- NCT06891066
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Interventions
- BIC/FTC/TAF Drug
- ISL Drug
- ULO Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 13, 2025
- Primary completion
- Aug 9, 2027
- Completion
- Sep 29, 2031
- Last update posted
- Oct 15, 2025
2025 – 2031
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Zuckerberg San Francisco General Hospital and Trauma Center ( Site 4107) | San Francisco | California | 94110 | — |
| Mills Clinical Research ( Site 4109) | West Hollywood | California | 90046 | — |
| Georgetown University Medical Center ( Site 4106) | Washington D.C. | District of Columbia | 20007 | — |
| Orlando Immunology Center ( Site 4103) | Orlando | Florida | 32803 | — |
| Triple O Research Institute ( Site 4111) | West Palm Beach | Florida | 33407 | — |
| Chatham County Health Department - Chatham CARE Center ( Site 4116) | Savannah | Georgia | 31401 | — |
| KC CARE Health Center ( Site 4101) | Kansas City | Missouri | 64111 | — |
| Regional Center for Infectious Diseases ( Site 4115) | Greensboro | North Carolina | 27401 | — |
| Central Texas Clinical Research ( Site 4100) | Austin | Texas | 78705 | — |
| Prism Health North Texas, Oak Cliff Health Center ( Site 4114) | Dallas | Texas | 75208 | — |
| DCOL Center for Clinical Research ( Site 4112) | Longview | Texas | 75605 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06891066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2025 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06891066 live on ClinicalTrials.gov.